FOLH1 and prostate cancer: In a first step, [225Ac]Ac-SibuDAB was evaluated in vitro for comparison with [225Ac]Ac-PSMA-617 and their 177Lu-labeled counterparts using PC-3 PIP (PSMA-positive) and PC-3 flu (PSMA-negative) prostate cancer cells.